Payment overview · 2025
General Payments
$47.00
2 reported records · 1 companies
Healthcare provider profile · identity verified
Britton Keith Bishop, M.D
Allopathic & Osteopathic Physicians|Family Medicine · LENOIR CITY, TN · NPI 1386617314
Verified facts
What the public records show
CMS Open Payments records show Britton Keith Bishop, M.D received $47.00 in general payments during 2025 across 2 reported records.
Inspire Medical Systems, Inc. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $47.00 | 100.0% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $47.00 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $47.00 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
None of this doctor’s payer companies has same-entity product evidence that passes the publication threshold. The site does not infer company ownership, affiliates, or generic manufacturers.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 495 | 147 |
| Amlodipine Besylate | Amlodipine Besylate | 397 | 112 |
| Levothyroxine Sodium | Levothyroxine Sodium | 347 | 94 |
| Pantoprazole Sodium | Pantoprazole Sodium | 312 | 86 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 281 | 91 |
| Lisinopril | Lisinopril | 277 | 91 |
| Metoprolol Succinate | Metoprolol Succinate | 241 | 77 |
| Gabapentin | Gabapentin | 237 | 65 |
| Omeprazole | Omeprazole | 227 | 64 |
| Eliquis | Apixaban | 217 | 40 |
| Losartan Potassium | Losartan Potassium | 191 | 57 |
| Metformin Hcl Er | Metformin Hcl | 180 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 177 | 51 |
| Meloxicam | Meloxicam | 157 | 47 |
| Zolpidem Tartrate | Zolpidem Tartrate | 152 | 32 |
| Montelukast Sodium | Montelukast Sodium | 147 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 133 | 43 |
| Potassium Chloride | Potassium Chloride | 132 | 44 |
| Furosemide | Furosemide | 125 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 122 | 39 |
| Celecoxib | Celecoxib | 119 | 41 |
| Trazodone Hcl | Trazodone Hcl | 117 | 37 |
| Carvedilol | Carvedilol | 113 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 109 | 39 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 109 | 35 |
| Sertraline Hcl | Sertraline Hcl | 106 | 32 |
| Irbesartan | Irbesartan | 104 | 33 |
| Simvastatin | Simvastatin | 104 | 34 |
| Ozempic | Semaglutide | 102 | 22 |
| Metformin Hcl | Metformin Hcl | 101 | 29 |
| Alendronate Sodium | Alendronate Sodium | 96 | 32 |
| Allopurinol | Allopurinol | 95 | 29 |
| Telmisartan | Telmisartan | 92 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 90 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 90 | 32 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 90 | 27 |
| Tramadol Hcl | Tramadol Hcl | 80 | 20 |
| Mounjaro | Tirzepatide | 75 | 12 |
| Clonazepam | Clonazepam | 65 | 15 |
| Bupropion Xl | Bupropion Hcl | 59 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 15 |
| Cefdinir | Cefdinir | 57 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 57 | 24 |
| Temazepam | Temazepam | 57 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 56 | 18 |
| Alprazolam | Alprazolam | 54 | 16 |
| Spironolactone | Spironolactone | 53 | 19 |
| Azithromycin | Azithromycin | 52 | 41 |
| Tizanidine Hcl | Tizanidine Hcl | 48 | 18 |
| Buspirone Hcl | Buspirone Hcl | 47 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 47 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | 12 |
| Lorazepam | Lorazepam | 46 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 46 | 32 |
| Pregabalin | Pregabalin | 46 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | 12 |
| Fenofibrate | Fenofibrate | 41 | 12 |
| Famotidine | Famotidine | 40 | 15 |
| Jardiance | Empagliflozin | 40 | suppressed |
| Lovastatin | Lovastatin | 39 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 38 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 35 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 35 | suppressed |
| Finasteride | Finasteride | 35 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | 11 |
| Klor-Con 10 | Potassium Chloride | 34 | suppressed |
| Mirtazapine | Mirtazapine | 34 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 18 |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Valsartan | Valsartan | 31 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Methylprednisolone | Methylprednisolone | 30 | 26 |
| Nystatin | Nystatin | 30 | 19 |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | suppressed |
| Prednisone | Prednisone | 28 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Cephalexin | Cephalexin | 24 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 23 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Fluconazole | Fluconazole | 21 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 14 |
| Droplet Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Leflunomide | Leflunomide | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $47.00 · 2 records | Inspire Medical Systems, Inc. | INSPIRE | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error